-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, listed companies in various industries are successively announcing their annual performance forecasts for 2021
.
Wind information data shows that as of January 16, 33 A-share listed pharmaceutical and biological companies have disclosed their 2021 performance forecasts
.
Among them, more than 80% of the pharmaceutical companies have positive results, but the sub-sectors of the industry are significantly differentiated, and companies in the traditional Chinese medicine and in vitro testing industries have performed better
.
From the perspective of net profit growth, Rejing Bio has significantly exceeded expectations.
The company expects to achieve a net profit of 2 billion to 2.
35 billion attributable to owners of the parent company in 2021, a year-on-year increase of 1684.
65% to 1996.
97%
.
As for the reasons for the substantial increase in performance, the company stated that it was mainly affected by the explosive growth of foreign trade orders for test kits and the substantial increase in overseas test kit revenue
.
According to public information, the main products of Rejing Biotech include in vitro diagnostic reagents and instruments.
The company is guided by market demand, with corporate innovation as the main body, and production, education, and research as the path.
A full-chain R&D system for in vitro diagnostics to instrument R&D
.
At present, its products are widely used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and emergency disease control
.
Among them, in the instrument business, the company's products mainly include up-conversion luminescence immunoassay analyzers and chemiluminescence immunoassay analyzers
.
The company has established a complete full-scenario immunodiagnosis technology platform that can meet the needs of different end users to meet the different needs of consumers; in terms of in vitro diagnosis, after years of development, the company has built a research and development platform for biologically active raw materials for in vitro diagnostic reagents, abnormal sugar chains.
Protein detection (sugar capture) research and development technology platform, magnetic particle chemiluminescence research and development technology platform, up-conversion luminescence research and development technology platform, colloidal gold immunochromatography research and development technology platform, enzyme-linked immunoassay research and development technology platform, molecular diagnosis research and development technology platform, instrument research and development technology Platform and other 8 major technology platforms, forming a closed-loop system for in vitro diagnostic R&D and production
.
Since 2021, the concept of testing has continued to strengthen.
In addition to Rejing Bio, the annual performance forecast of in vitro testing companies such as Mingde Bio and Kaipu Bio has also been relatively bright.
, 120.
59%~137.
14%
.
With the continuous improvement of the country's medical level, the growth of residents' disposable income and the improvement of living standards, China's in vitro diagnostic industry has maintained a growth rate of about 18% in recent years, far exceeding the global average
.
With the implementation of the "Healthy China 2030" strategy, as well as the expansion of the demand for early diagnosis and early screening, precision medicine, and doctors and patients from the treatment of the disease to the treatment of the disease before, the industry expects a considerable market space for in vitro diagnostics
.
In 2020, the market size of China's in vitro diagnostics is 78.
9 billion yuan, and the market size is expected to reach 104.
3 billion yuan by 2022
.
In addition to in vitro diagnostics, the performance of traditional Chinese medicine companies is also remarkable
.
Among them, Zhongsheng Pharmaceutical expects to turn losses into profits in 2021
.
During the reporting period, the net profit attributable to shareholders of the listed company was 330 million to 390 million
.
Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will be 170 million to 187 million yuan, an increase of 91.
44% to 110.
58% over the same period last year
.
In 2021, the Chinese Medicine Index will rise by 31.
71%, outperforming many other sub-sectors
.
From the perspective of the industry, the outstanding performance of the traditional Chinese medicine sector is mainly due to the support of a series of favorable policies.
At the same time, the approval of traditional Chinese medicine has been accelerated.
The number of innovative traditional Chinese medicine drugs approved in 2021 has reached 11, and the number of approvals has reached a new high in the past five years
.
.
Wind information data shows that as of January 16, 33 A-share listed pharmaceutical and biological companies have disclosed their 2021 performance forecasts
.
Among them, more than 80% of the pharmaceutical companies have positive results, but the sub-sectors of the industry are significantly differentiated, and companies in the traditional Chinese medicine and in vitro testing industries have performed better
.
From the perspective of net profit growth, Rejing Bio has significantly exceeded expectations.
The company expects to achieve a net profit of 2 billion to 2.
35 billion attributable to owners of the parent company in 2021, a year-on-year increase of 1684.
65% to 1996.
97%
.
As for the reasons for the substantial increase in performance, the company stated that it was mainly affected by the explosive growth of foreign trade orders for test kits and the substantial increase in overseas test kit revenue
.
According to public information, the main products of Rejing Biotech include in vitro diagnostic reagents and instruments.
The company is guided by market demand, with corporate innovation as the main body, and production, education, and research as the path.
A full-chain R&D system for in vitro diagnostics to instrument R&D
.
At present, its products are widely used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and emergency disease control
.
Among them, in the instrument business, the company's products mainly include up-conversion luminescence immunoassay analyzers and chemiluminescence immunoassay analyzers
.
The company has established a complete full-scenario immunodiagnosis technology platform that can meet the needs of different end users to meet the different needs of consumers; in terms of in vitro diagnosis, after years of development, the company has built a research and development platform for biologically active raw materials for in vitro diagnostic reagents, abnormal sugar chains.
Protein detection (sugar capture) research and development technology platform, magnetic particle chemiluminescence research and development technology platform, up-conversion luminescence research and development technology platform, colloidal gold immunochromatography research and development technology platform, enzyme-linked immunoassay research and development technology platform, molecular diagnosis research and development technology platform, instrument research and development technology Platform and other 8 major technology platforms, forming a closed-loop system for in vitro diagnostic R&D and production
.
Since 2021, the concept of testing has continued to strengthen.
In addition to Rejing Bio, the annual performance forecast of in vitro testing companies such as Mingde Bio and Kaipu Bio has also been relatively bright.
, 120.
59%~137.
14%
.
With the continuous improvement of the country's medical level, the growth of residents' disposable income and the improvement of living standards, China's in vitro diagnostic industry has maintained a growth rate of about 18% in recent years, far exceeding the global average
.
With the implementation of the "Healthy China 2030" strategy, as well as the expansion of the demand for early diagnosis and early screening, precision medicine, and doctors and patients from the treatment of the disease to the treatment of the disease before, the industry expects a considerable market space for in vitro diagnostics
.
In 2020, the market size of China's in vitro diagnostics is 78.
9 billion yuan, and the market size is expected to reach 104.
3 billion yuan by 2022
.
In addition to in vitro diagnostics, the performance of traditional Chinese medicine companies is also remarkable
.
Among them, Zhongsheng Pharmaceutical expects to turn losses into profits in 2021
.
During the reporting period, the net profit attributable to shareholders of the listed company was 330 million to 390 million
.
Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will be 170 million to 187 million yuan, an increase of 91.
44% to 110.
58% over the same period last year
.
In 2021, the Chinese Medicine Index will rise by 31.
71%, outperforming many other sub-sectors
.
From the perspective of the industry, the outstanding performance of the traditional Chinese medicine sector is mainly due to the support of a series of favorable policies.
At the same time, the approval of traditional Chinese medicine has been accelerated.
The number of innovative traditional Chinese medicine drugs approved in 2021 has reached 11, and the number of approvals has reached a new high in the past five years
.
